Tags

Type your tag names separated by a space and hit enter

Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience.
J Surg Oncol. 2005 Mar 15; 89(4):239-43.JS

Abstract

BACKGROUND

Aim of our study was to evaluate the efficacy of multiagent intensive preoperative chemotherapy in patients with Ewing sarcoma family tumors (ESFT), in order to succeed a better percentage of necrosis before surgical resection.

PROCEDURE

Eighteen patients with ESFT were treated with the same multiagent intensive preoperative protocol. 5/18 patients had bone Ewings sarcoma (EWS) and 13/18 had peripheral primitive neuroectodermal tumor (PNET). None had metastases at diagnosis. Chemotherapy consisted of 5 or 6 cycles with vincristine, cisplatin, cyclophosphamide, and Adriamycin, followed by 12 cycles of vincristine, cyclophosphamide, and actinomycin-D. Five patients with EWS underwent total resection after 5-6 cycles of preoperative chemotherapy and prosthetic replacement was performed in two of them. In 3/13 patients with PNET the tumor was resected at diagnosis and in 1/13 after 5 cycles of chemotherapy, while 9/13 patients received chemotherapy only and/or radiotherapy.

RESULTS

In patients with EWS, the histologic specimens of the resected tumors showed that tissue necrosis was 100% in four patients and 95% in one patient. The good histologic response reflects the effectiveness of this regimen in all ESFT. No patient had topical recurrence or developed metastatic disease during follow-up period (2-13 years, mean time 7.4 years). All patients had the scheduled cycles without delays or dose reductions. There were no major side effects of chemotherapy.

CONCLUSIONS

The intensive chemotherapy schedule, comprising of 5-6 cycles preoperatively, seems to maximize the percentage of tumor necrosis, thus improving outcome. Our study implies that this combined therapy may improve the prognosis of ESFT.

Authors+Show Affiliations

Hematology-Oncology Unit, First Department of Pediatrics of Athens University, Greece. mmoschov@med.uoa.gr <mmoschov@med.uoa.gr>No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15726621

Citation

Moschovi, Maria, et al. "Favorable Outcome of Ewing Sarcoma Family Tumors to Multiagent Intensive Preoperative Chemotherapy: a Single Institution Experience." Journal of Surgical Oncology, vol. 89, no. 4, 2005, pp. 239-43.
Moschovi M, Trimis G, Stefanaki K, et al. Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience. J Surg Oncol. 2005;89(4):239-43.
Moschovi, M., Trimis, G., Stefanaki, K., Anastasopoulos, J., Syriopoulou, V., Koultouki, E., & Tzortzatou-Stathopoulou, F. (2005). Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience. Journal of Surgical Oncology, 89(4), 239-43.
Moschovi M, et al. Favorable Outcome of Ewing Sarcoma Family Tumors to Multiagent Intensive Preoperative Chemotherapy: a Single Institution Experience. J Surg Oncol. 2005 Mar 15;89(4):239-43. PubMed PMID: 15726621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience. AU - Moschovi,Maria, AU - Trimis,Georgios, AU - Stefanaki,Kalliopi, AU - Anastasopoulos,John, AU - Syriopoulou,Vassiliki, AU - Koultouki,Eleutheria, AU - Tzortzatou-Stathopoulou,Fotini, PY - 2005/2/24/pubmed PY - 2005/3/23/medline PY - 2005/2/24/entrez SP - 239 EP - 43 JF - Journal of surgical oncology JO - J Surg Oncol VL - 89 IS - 4 N2 - BACKGROUND: Aim of our study was to evaluate the efficacy of multiagent intensive preoperative chemotherapy in patients with Ewing sarcoma family tumors (ESFT), in order to succeed a better percentage of necrosis before surgical resection. PROCEDURE: Eighteen patients with ESFT were treated with the same multiagent intensive preoperative protocol. 5/18 patients had bone Ewings sarcoma (EWS) and 13/18 had peripheral primitive neuroectodermal tumor (PNET). None had metastases at diagnosis. Chemotherapy consisted of 5 or 6 cycles with vincristine, cisplatin, cyclophosphamide, and Adriamycin, followed by 12 cycles of vincristine, cyclophosphamide, and actinomycin-D. Five patients with EWS underwent total resection after 5-6 cycles of preoperative chemotherapy and prosthetic replacement was performed in two of them. In 3/13 patients with PNET the tumor was resected at diagnosis and in 1/13 after 5 cycles of chemotherapy, while 9/13 patients received chemotherapy only and/or radiotherapy. RESULTS: In patients with EWS, the histologic specimens of the resected tumors showed that tissue necrosis was 100% in four patients and 95% in one patient. The good histologic response reflects the effectiveness of this regimen in all ESFT. No patient had topical recurrence or developed metastatic disease during follow-up period (2-13 years, mean time 7.4 years). All patients had the scheduled cycles without delays or dose reductions. There were no major side effects of chemotherapy. CONCLUSIONS: The intensive chemotherapy schedule, comprising of 5-6 cycles preoperatively, seems to maximize the percentage of tumor necrosis, thus improving outcome. Our study implies that this combined therapy may improve the prognosis of ESFT. SN - 0022-4790 UR - https://www.unboundmedicine.com/medline/citation/15726621/Favorable_outcome_of_Ewing_sarcoma_family_tumors_to_multiagent_intensive_preoperative_chemotherapy:_a_single_institution_experience_ L2 - https://doi.org/10.1002/jso.20206 DB - PRIME DP - Unbound Medicine ER -